Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydroxypropyltetrahydropyrantriol, widely known by the trade name **Pro-Xylane**, is a C-glycoside derivative developed by L'Oréal. It is a sugar-protein hybrid derived from xylose, a natural sugar found in beech trees. Primarily used in anti-aging skincare formulations, it acts by stimulating the biosynthesis of glycosaminoglycans (GAGs), such as hyaluronic acid and heparan sulfate, within the extracellular matrix of the dermis and epidermis. By increasing GAG production, it enhances the skin's moisture-retaining capacity and structural integrity, which helps to reduce the appearance of wrinkles and improve skin barrier function. It has been investigated in clinical settings for its ability to restore skin barrier kinetics in elderly subjects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydroxypropyltetrahydropyrantriol.